936-48-1

Basic information

• Product Name: 3-phenyl-4,5-dihydro-1H-pyrazole
• Synonyms: 3-phenyl-4,5-dihydro-1H-pyrazole
• CAS NO: 936-48-1
• Molecular Weight: 146.192
• Mol File: 936-48-1.mol

Chemical Properties

• CAS DataBase Reference: 3-phenyl-4,5-dihydro-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-phenyl-4,5-dihydro-1H-pyrazole(936-48-1)
• EPA Substance Registry System: 3-phenyl-4,5-dihydro-1H-pyrazole(936-48-1)

Safety Data

• Hazardous Substances Data: 936-48-1(Hazardous Substances Data)

Upstream product

• 936-59-4 3-chloropropiophenone 
• 879-72-1 3-(dimethylamino)propiophenone hydrochloride 
• 3506-36-3 3-dimethylaminopropiophenone 
• 50-00-0 formaldehyd 
• 98-86-2 acetophenone 
• 186581-53-3 diazomethane 
• 100-42-5 styrene 
• 768-03-6 Phenyl vinyl ketone 

Downstream Products

• 1158827-58-7 C₁₅H₁₃N₃O₄S 
• 1158827-59-8 C₁₅H₁₃BrN₂O₂S 
• 361442-65-1 1-nicotinoyl-3-phenyl-2-pyrazoline 
• 361443-36-9 1-(5-bromonicotinoyl)-3-phenyl-2-pyrazoline 
• 898128-03-5 1-(3-phenyl-4,5-dihydro-pyrazol-1-yl)-cyclohexanecarbonitrile 
• 898127-97-4 2-methyl-2-(3-phenyl-4,5-dihydro-pyrazol-1-yl)-propionitrile 

Relevant articles and documents

Synthesis and antiviral activities of novel acylhydrazone derivatives targeting HIV-1 capsid protein

HIV-1 capsid protein (CA) plays important roles in the viral replication cycle. A number of acylhydrazone derivatives that act as inhibitors of HIV-1 CA assembly, were designed and synthesized. The synthesized compounds were tested for their antiviral activities and cytotoxicities using CEM cells. Some derivatives also were assayed for their ability to inhibit HIV-1 CA assembly in vitro. Among them, compounds 14f and 14i display the most promising potency with EC50 values of 0.21 and 0.17 μΜ, respectively.

SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS

This invention concerns sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1), wherein the symbols have the meanings given in the description.

Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof

Using a compound selected from compounds represented by the following formula (1) (which include 3-phenyl-2-pyrazoline derivatives and 3-phenyl-tetrahydropyridazine derivatives) and pharmacologically acceptable salts thereof, an agent is provided which can activate glutamic acid transporter and which is useful for prevention and/treatment of cerebral ischemia (cerebral infarct and brain edema), amyotrophic lateral sclerosis (ALS), etc., all caused by glutamic acid toxicity.